ERβ splice variant expression in four large cohorts of human breast cancer patient tumors

[1]  K. Dahlman-Wright,et al.  Estrogen receptor beta in breast cancer , 2014, Molecular and Cellular Endocrinology.

[2]  C. Reynolds,et al.  Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody , 2012, Journal of cellular biochemistry.

[3]  R Peto,et al.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[4]  Liang Cheng,et al.  Estrogen receptor β2 and β5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion , 2010, Endocrine-related cancer.

[5]  M. Shupnik,et al.  ERβ in breast cancer—Onlooker, passive player, or active protector? , 2008, Steroids.

[6]  I. Ellis,et al.  Nuclear and Cytoplasmic Expression of ERβ1, ERβ2, and ERβ5 Identifies Distinct Prognostic Outcome for Breast Cancer Patients , 2008, Clinical Cancer Research.

[7]  Takuji Iwase,et al.  Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Bull,et al.  Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Node–Negative Cohort , 2008, Clinical Cancer Research.

[9]  J. Gustafsson,et al.  A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells , 2008, Oncogene.

[10]  S. Ho,et al.  Estrogen receptor (ER)-β isoforms: A key to understanding ER-β signaling , 2006, Proceedings of the National Academy of Sciences.

[11]  M. García-Closas,et al.  Established breast cancer risk factors by clinically important tumour characteristics , 2006, British Journal of Cancer.

[12]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2006, Breast Cancer Research and Treatment.

[13]  I. Poola,et al.  Estrogen receptors beta4 and beta5 are full length functionally distinct ERβ isoforms , 2005, Endocrine.

[14]  S. Khosla,et al.  Estrogen receptor α and β heterodimers exert unique effects on estrogen- and tamoxifen- dependent gene expression in human U2OS osteosarcoma cells , 2005 .

[15]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[16]  L. Murphy,et al.  Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. , 2005, Journal of molecular endocrinology.

[17]  Heidi L. Weiss,et al.  Low Levels of Estrogen Receptor β Protein Predict Resistance to Tamoxifen Therapy in Breast Cancer , 2004, Clinical Cancer Research.

[18]  J. Gustafsson,et al.  Estrogen Receptor β (ERβ) Level but Not Its ERβcx Variant Helps to Predict Tamoxifen Resistance in Breast Cancer , 2004, Clinical Cancer Research.

[19]  A. Lazaris,et al.  The favourable prognostic value of oestrogen receptor β immunohistochemical expression in breast cancer , 2004, Journal of Clinical Pathology.

[20]  Y. Omoto,et al.  Estrogen receptor (ER) β1 and ERβcx/β2 inhibit ERα function differently in breast cancer cell line MCF7 , 2003, Oncogene.

[21]  E. Leygue,et al.  Putative functional characteristics of human estrogen receptor-beta isoforms. , 2003, Journal of molecular endocrinology.

[22]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[23]  Chris Albanese,et al.  Opposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression* , 2002, The Journal of Biological Chemistry.

[24]  Y. Ouchi,et al.  Molecular cloning and characterization of human estrogen receptor βcx: A potential inhibitor of estrogen action in human , 1998 .

[25]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[26]  S. Bull,et al.  neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Y. Ouchi,et al.  The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. , 1998, Biochemical and biophysical research communications.

[28]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Stephen M. Hewitt,et al.  Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression , 2013, Breast Cancer Research and Treatment.

[30]  B. Katzenellenbogen,et al.  Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. , 2010, Molecular endocrinology.

[31]  D. Rimm,et al.  Quantitative, fluorescence-based in-situ assessment of protein expression. , 2009, Methods in molecular biology.